ALPCO Diagnostics Exclusively Offers Animal NGAL Assays from BioPorto by PR.com

VIEWS: 11 PAGES: 3

More Info
									ALPCO Diagnostics Exclusively Offers Animal NGAL Assays from BioPorto

Salem, NH, June 17, 2010 --(PR.com)-- BioPorto Diagnostics has awarded ALPCO Diagnostics
exclusive distributorship for its animal NGAL ELISAs to the North American market. BioPorto's
prominence is unrivaled in immunoassays for measuring NGAL (neutrophil gelatinase associated
lipocalin) - the breakthrough kidney injury marker that was brought to market first by BioPorto. In
Europe, NGAL is used to diagnose Acute Kidney Injury (AKI) within a few hours after an AKI causing
event has occurred - a vast improvement over all other methods used to date. The availability of these
assays can translate into considerable improvements in toxicity testing for the medical and drug industry
in North America.

Sean Conley, President of ALPCO Diagnostics is excited about BioPorto's NGAL Assays: “We are very
pleased to offer the BioPorto NGAL products to the North American life science research markets.
BioPorto has a proven reputation for producing high quality immunoassay products and offers the most
comprehensive NGAL product range including Canine NGAL ELISA, Mouse NGAL ELISA, and Rat
NGAL ELISA with Porcine NGAL ELISA and Monkey NGAL ELISA launching soon.”

“ALPCO is a well established and reputable company in the life sciences industry and we are very
pleased to have the opportunity to work together. A primary focus will be the promotion of our animal
NGAL product line aimed at the pharmaceutical industry - ALPCO's renowned competencies in this area
coupled with the unmatched depth of our NGAL portfolio is a winning combination” says Thea Olesen,
CEO, BioPorto Diagnostics.

For more information, visit www.NGAL.com. Alternatively BioPorto will be presenting scientific posters
at the upcoming World Pharmaceutical Congress on some of latest breakthroughs with these assays while
ALPCO will be available at booth #18 in the exhibitor area.

About ALPCO Diagnostics
Founded in 1990, ALPCO Diagnostics is an importer and distributor of high quality research
immunoassay kits. The company's goals then, as now, have been to offer a diverse line of assays that
appeal to its broad customer base while providing exceptional customer service and product support. In
recent years, ALPCO has solidified its place in the market not only as a distributor but as a developer and
manufacturer of immunoassays as well.

About BioPorto Diagnostics
BioPorto develops and markets antibodies and antibody-based products, including tests to diagnose
human disease, both for the benefit of individual patients and to promote efficiency in the health sector.
BioPorto's developments include tests to diagnose and monitor acute kidney damage in humans and for
basic research in animals. BioPorto's strategy is to develop new methods based on its antibody portfolio
that can be patented or have other competitive advantages and achieve a wide use in the diagnosis of
various diseases. BioPorto is a Danish company founded in 2000 and listed on the NASDAQ OMX in
Copenhagen.



                                                   Page 1/3
                                PR.com Press Release Distribution   Terms of Use
###




                         Page 2/3
      PR.com Press Release Distribution   Terms of Use
Contact Information:
ALPCO Diagnostics
Dan Keefe
800-592-5726 x241
web@alpco.com
www.alpco.com


Online Version of Press Release:
You can read the online version of this press release at: http://www.pr.com/press-release/242407


News Image:




                                                  Page 3/3
                               PR.com Press Release Distribution   Terms of Use

								
To top